Header Logo



This is a "connection" page, showing publications co-authored by Douglas Golenbock and Stuart Levitz.
Connection Strength

  1. Levitz SM, Golenbock DT. Beyond empiricism: informing vaccine development through innate immunity research. Cell. 2012 Mar 16; 148(6):1284-92.
    View in: PubMed
    Score: 0.433
  2. Levitz SM, Tabuni A, Kozel TR, MacGill RS, Ingalls RR, Golenbock DT. Binding of Cryptococcus neoformans to heterologously expressed human complement receptors. Infect Immun. 1997 Mar; 65(3):931-5.
    View in: PubMed
    Score: 0.152
  3. Levitz SM, Tabuni A, Nong SH, Golenbock DT. Effects of interleukin-10 on human peripheral blood mononuclear cell responses to Cryptococcus neoformans, Candida albicans, and lipopolysaccharide. Infect Immun. 1996 Mar; 64(3):945-51.
    View in: PubMed
    Score: 0.142
  4. Levitz SM, Tabuni A, Kornfeld H, Reardon CC, Golenbock DT. Production of tumor necrosis factor alpha in human leukocytes stimulated by Cryptococcus neoformans. Infect Immun. 1994 May; 62(5):1975-81.
    View in: PubMed
    Score: 0.125
  5. Sau K, Mambula SS, Latz E, Henneke P, Golenbock DT, Levitz SM. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J Biol Chem. 2003 Sep 26; 278(39):37561-8.
    View in: PubMed
    Score: 0.059
  6. Mambula SS, Sau K, Henneke P, Golenbock DT, Levitz SM. Toll-like receptor (TLR) signaling in response to Aspergillus fumigatus. J Biol Chem. 2002 Oct 18; 277(42):39320-6.
    View in: PubMed
    Score: 0.056
  7. Shoham S, Huang C, Chen JM, Golenbock DT, Levitz SM. Toll-like receptor 4 mediates intracellular signaling without TNF-alpha release in response to Cryptococcus neoformans polysaccharide capsule. J Immunol. 2001 Apr 01; 166(7):4620-6.
    View in: PubMed
    Score: 0.051
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.